SCHEMBL13580950

SCHEMBL13580950

CCCCC(Oc1cc(Br)ccc1Oc1ccc(C(C)(C)C)cc1)C(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 2/20 0.38
THRB P10828 1/20 0.36
NR1I2 O75469 1/20 0.36
NPSR1 Q6W5P4 3/20 0.35
GAA P10253 1/20 0.35
XBP1 P17861 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SLC6A4 P31645 1/20 0.35
PTGER1 P34995 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
TBXA2R P21731 2/20 0.34
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13580954 0.96 ALDH2 (0.38) ALDH2THRBNR1I2NPSR1GAA
SCHEMBL13580940 0.84 EPHX2 (0.39) ALDH2NR1I2NPSR1GAAXBP1
SCHEMBL13580952 0.84 ALDH2 (0.40) ALDH2NPSR1GAAXBP1ATM
SCHEMBL13580930 0.83 ALDH2 (0.39) ALDH2NR1I2NPSR1GAAXBP1
SCHEMBL13580951 0.81 SCN9A (0.40) ALDH2
SCHEMBL13580956 0.80 ALDH2 (0.40) ALDH2NPSR1GAAXBP1ATM
SCHEMBL13580957 0.80 ALDH2 (0.41) ALDH2NR1I2SLC6A4
SCHEMBL13580933 0.79 ALDH2 (0.39) ALDH2NR1I2SLC6A4
SCHEMBL8468433 0.78 NPSR1 (0.40) ALDH2THRBNR1I2NPSR1GAA
SCHEMBL13580955 0.78 SCN9A (0.40) ALDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 US disclosed
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 ALDH2 3445/4885THRB 1211/4885NR1I2 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.